ArticleBMJ open gastroenterology2018

Evaluation of amnion-derived mesenchymal stem cells for treatment-resistant moderate Crohn's disease: study protocol for a phase I/II, dual-centre, open-label, uncontrolled, dose-response trial.

Shinsuke Otagiri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.